166 related articles for article (PubMed ID: 31489711)
41. Overexpression of CD 133 and BCL-2 in non-small cell lung cancer with neuroendocrine differentiation after transformation in ALK rearrangement-positive adenocarcinoma.
Koyama K; Katsurada N; Jimbo N; Tachihara M; Tamura D; Nakata K; Nagano T; Yamamoto M; Kamiryo H; Kobayashi K; Itoh T; Nishimura Y
Pathol Int; 2019 May; 69(5):294-299. PubMed ID: 30900377
[TBL] [Abstract][Full Text] [Related]
42. ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma.
Dacic S; Villaruz LC; Abberbock S; Mahaffey A; Incharoen P; Nikiforova MN
Oncotarget; 2016 Dec; 7(50):82943-82952. PubMed ID: 27769042
[TBL] [Abstract][Full Text] [Related]
43. Clinical utility of haptoglobin in combination with CEA, NSE and CYFRA21-1 for diagnosis of lung cancer.
Wang B; He YJ; Tian YX; Yang RN; Zhu YR; Qiu H
Asian Pac J Cancer Prev; 2014; 15(22):9611-4. PubMed ID: 25520076
[TBL] [Abstract][Full Text] [Related]
44. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
Solomon BJ; Besse B; Bauer TM; Felip E; Soo RA; Camidge DR; Chiari R; Bearz A; Lin CC; Gadgeel SM; Riely GJ; Tan EH; Seto T; James LP; Clancy JS; Abbattista A; Martini JF; Chen J; Peltz G; Thurm H; Ou SI; Shaw AT
Lancet Oncol; 2018 Dec; 19(12):1654-1667. PubMed ID: 30413378
[TBL] [Abstract][Full Text] [Related]
45. Baseline and On-Treatment Characteristics of Serum Tumor Markers in Stage IV Oncogene-Addicted Adenocarcinoma of the Lung.
Noonan SA; Patil T; Gao D; King GG; Thibault JR; Lu X; Bunn PA; Doebele RC; Purcell WT; Barón AE; Camidge DR
J Thorac Oncol; 2018 Jan; 13(1):134-138. PubMed ID: 28843358
[TBL] [Abstract][Full Text] [Related]
46. Preoperative CT features for prediction of ALK gene rearrangement in lung adenocarcinomas.
Wang H; Wang Y; Zhang H; Han Y; Li Q; Ye Z
Clin Radiol; 2020 Jul; 75(7):562.e21-562.e29. PubMed ID: 32307109
[TBL] [Abstract][Full Text] [Related]
47. Resected stage I anaplastic lymphoma kinase-positive lung adenocarcinoma has a negative impact on recurrence-free survival.
Fujibayashi Y; Tane S; Kitazume M; Kuroda S; Kimura K; Kitamura Y; Nishio W
Thorac Cancer; 2022 Apr; 13(8):1109-1116. PubMed ID: 35274461
[TBL] [Abstract][Full Text] [Related]
48. Lactate dehydrogenase and serum tumor markers for predicting metastatic status in geriatric patients with lung adenocarcinoma.
Ren X; Zhang Y; Lyu Y; Jin B; Guo H; Wu J; Li X; Liu X
Cancer Biomark; 2019; 26(2):139-150. PubMed ID: 31356196
[TBL] [Abstract][Full Text] [Related]
49. Epidermal Growth Factor Receptor (EGFR) Mutations and Anaplastic Lymphoma Kinase/Oncogene or C-Ros Oncogene 1 (ALK/ROS1) Fusions Inflict Non-Small Cell Lung Cancer (NSCLC) Female Patients Older Than 60 Years of Age.
Ke L; Xu M; Jiang X; Sun X
Med Sci Monit; 2018 Dec; 24():9364-9369. PubMed ID: 30580372
[TBL] [Abstract][Full Text] [Related]
50. Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants.
Cha YJ; Kim HR; Shim HS
J Transl Med; 2016 Oct; 14(1):296. PubMed ID: 27756333
[TBL] [Abstract][Full Text] [Related]
51. Lung adenocarcinoma with concurrent ALK and ROS1 rearrangement: A case report and review of the literatures.
Deng H; Liu C; Zhang G; Wang X; Liu Y
Pathol Res Pract; 2018 Dec; 214(12):2103-2105. PubMed ID: 30327151
[TBL] [Abstract][Full Text] [Related]
52. Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer.
Kron A; Alidousty C; Scheffler M; Merkelbach-Bruse S; Seidel D; Riedel R; Ihle MA; Michels S; Nogova L; Fassunke J; Heydt C; Kron F; Ueckeroth F; Serke M; Krüger S; Grohe C; Koschel D; Benedikter J; Kaminsky B; Schaaf B; Braess J; Sebastian M; Kambartel KO; Thomas R; Zander T; Schultheis AM; Büttner R; Wolf J
Ann Oncol; 2018 Oct; 29(10):2068-2075. PubMed ID: 30165392
[TBL] [Abstract][Full Text] [Related]
53. Clinicopathological Features of ALK Expression in 9889 Cases of Non-small-Cell Lung Cancer and Genomic Rearrangements Identified by Capture-Based Next-Generation Sequencing: A Chinese Retrospective Analysis.
Zhao R; Zhang J; Han Y; Shao J; Zhu L; Xiang C; Zhang Q; Teng H; Qin G; Zhao L; Ye M; Zhao J; Ding W
Mol Diagn Ther; 2019 Jun; 23(3):395-405. PubMed ID: 30840206
[TBL] [Abstract][Full Text] [Related]
54. Advanced adenocarcinoma of the lung: comparison of CT characteristics of patients with anaplastic lymphoma kinase gene rearrangement and those with epidermal growth factor receptor mutation.
Choi CM; Kim MY; Hwang HJ; Lee JB; Kim WS
Radiology; 2015 Apr; 275(1):272-9. PubMed ID: 25575117
[TBL] [Abstract][Full Text] [Related]
55. Anaplastic lymphoma kinase gene rearrangements in cytological samples of non-small cell lung cancer: comparison with histological assessment.
Proietti A; Alì G; Pelliccioni S; Lupi C; Sensi E; Boldrini L; Servadio A; Chella A; Ribechini A; Cappuzzo F; Miccoli M; Fontanini G
Cancer Cytopathol; 2014 Jun; 122(6):445-53. PubMed ID: 24648382
[TBL] [Abstract][Full Text] [Related]
56. Frequency of anaplastic lymphoma kinase rearrangements in Moroccan patients with non small cell lung cancer: a multi-institutional national retrospective study.
El Yacoubi H; Sow ML; Kettani F; Gamra L; Mestari A; Jabri L; Elghissassi I; Errihani H
BMC Cancer; 2020 May; 20(1):479. PubMed ID: 32460789
[TBL] [Abstract][Full Text] [Related]
57. Dramatic Response to Lorlatinib in a Heavily Pretreated Lung Adenocarcinoma Patient Harboring G1202R Mutation and a Synchronous Novel R1192P ALK Point Mutation.
Baglivo S; Ricciuti B; Ludovini V; Metro G; Siggillino A; De Giglio A; Chiari R
J Thorac Oncol; 2018 Aug; 13(8):e145-e147. PubMed ID: 30049377
[No Abstract] [Full Text] [Related]
58. Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in
Pailler E; Faugeroux V; Oulhen M; Mezquita L; Laporte M; Honoré A; Lecluse Y; Queffelec P; NgoCamus M; Nicotra C; Remon J; Lacroix L; Planchard D; Friboulet L; Besse B; Farace F
Clin Cancer Res; 2019 Nov; 25(22):6671-6682. PubMed ID: 31439588
[TBL] [Abstract][Full Text] [Related]
59. Comparison of clinical characteristics between patients with ALK-positive and EGFR-positive lung adenocarcinoma.
Kang HJ; Lim HJ; Park JS; Cho YJ; Yoon HI; Chung JH; Lee JH; Lee CT
Respir Med; 2014 Feb; 108(2):388-94. PubMed ID: 24361161
[TBL] [Abstract][Full Text] [Related]
60. The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients.
Dal Bello MG; Filiberti RA; Alama A; Orengo AM; Mussap M; Coco S; Vanni I; Boccardo S; Rijavec E; Genova C; Biello F; Barletta G; Rossi G; Tagliamento M; Maggioni C; Grossi F
J Transl Med; 2019 Mar; 17(1):74. PubMed ID: 30849967
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]